This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

       

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

Popup

Educational Event Schedules

EHR Resources

Order SHINGRIX

CDC Supply Information

Vaccine Info Statement

Medical Inquiries

Questions About SHINGRIX?
Call: 1 (800) 772-9292
Available Monday - Friday
8:30am to 5:30pm ET

Reconstitution & Administration

Please refer to the full Prescribing Information for SHINGRIX for full details.1

  • Refrigerate between 2º and 8ºC (36º and 46ºF). Protect vials from light. DO NOT FREEZE (discard if frozen)
  • Reconstitute and use immediately
  • Reconstituted vaccine is stable for 6 hours refrigerated between 2º and 8ºC (36º and 46ºF) and should be discarded after 6 hours. Do not freeze. Discard if the reconstituted vaccine has been frozen

Reconstitution Step-by-Step1

Vial 1 of 2
AS01B Adjuvant Suspension Component
(liquid; blue-green cap/red ring)

Vial 2 of 2
Lyophilized VZV gE Antigen Component
(powder; brown cap/green ring)

Cleanse both vial stoppers. Using a sterile needle and sterile syringe, withdraw the entire contents of the vial containing the adjuvant suspension component (liquid) by slightly tilting the vial. Vial 1 of 2.

Slowly transfer entire contents of syringe into the lyophilized gE antigen component vial (powder). Vial 2 of 2.

Gently shake the vial to thoroughly mix contents until powder is completely dissolved. The reconstituted vaccine should be an opalescent, colorless to pale brownish liquid.

Reconstituted vaccine

 

After reconstitution, withdraw 0.5 mL from the vial containing the reconstituted vaccine and administer intramuscularly.

 

VZV=varicella zoster virus; gE=glycoprotein E.

You may also be interested in:

Storage & Dosing

Learn how to store SHINGRIX and about the importance of proper dosing.

Video Center

Watch a range of informative videos, including highlights of pivotal trials and MOA and reconstitution videos.

Coverage & Coding

Get product coding and coverage details for commercial medical benefit and Medicare Part D insurance.

Reference: 1. Prescribing Information for SHINGRIX.

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
  • Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%)
  • Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%)
  • SHINGRIX was not studied in pregnant or lactating women, and it is unknown if it is excreted in human milk. Therefore, it cannot be established whether there is vaccine-associated risk with SHINGRIX in pregnant women or if there are effects on breastfed infants or milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Trademarks are property of their respective owners.